|Table of Contents|

Clinical analysis of concurrent versus sequential chemoradiotherapy for 85 medically inoperable patients with locally advanced non-small-cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 01
Page:
56-59
Research Field:
Publishing date:

Info

Title:
Clinical analysis of concurrent versus sequential chemoradiotherapy for 85 medically inoperable patients with locally advanced non-small-cell lung cancer
Author(s):
Jiang Yong; Cui Lin; He Xuejun; Wu Xingjun; Zhou Xiangrong; Liu Jianjun; Chen Gaoyang; Liu Xingxiang; Li Yang
Department of Oncology，Taizhou Second People's Hospital，Jiangsu Taizhou 225500，China.
Keywords:
non-small-cell lung cancer; concurrent chemoradiotherapy; three-dimensional conformal radiotherapy; paclitaxel; cisplatin
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2017.01.015
Abstract:
Objective：To evaluate the therapeutic efficacy and treatment-related toxicity of concurrent versus sequential chemoradiotherapy for medically inoperable patients with locally advanced non-small-cell lung cancer(NSCLC).Methods：Clinical data of 85 patients with stage III NSCLC who received concurrent or sequential chemoradiotherapy as initial treatment between July 2011 and December 2013 was reviewed.45 patients who received concurrent chemoradiotherapy were included in group A，40 patients who received sequential chemoradiotherapy were enrolled in group B.Three-dimensional conformal radiotherapy(3D-CRT）was applied to all patients.Total radiotherapy doses of 60Gy in 30 fractions were delivered.Paclitaxel plus cisplatin was administered as concurrent chemotherapy in group A，as sequential chemotherapy in group B.The efficacy，toxicity，1-，and 2-year survival rate of concurrent chemoradiotherapy were retrospectively analyzed.Results：All the 85 patients could be evaluated，the follow-up rate was 100%.The response rates for group A and group B were 73.3% and 50.0%(P<0.05).1-year local control rates were 51.1% and 30.0%(P<0.05).1-year survival rate were 62.2% and 42.5%(P>0.05)，2-year survival rates were 37.8% and 17.5%(P<0.05).The rates of grade≥III radiation pneumonitis，esophagitis and hematologic toxicity in group A were 6.7%，11.1% and 28.9%，respectively，group B were 5.0%，10.0% and 27.5%.Toxic effects in two groups were tolerable for all of the patients.Conclusion：Concurrent chemoradiotherapy is effective and well tolerated for locally advanced NSCLC，it is better than sequential chemoradiotherapy as a standard therapeutic approach for patients with unresectable locally advanced NSCLC.

References:

［1］Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015［J］.CA Cancer J Clin，2016，66(2)：115-132.
［2］Blumenthal GM，Karuri SW，Zhang H，et al.Overall response rate，progression-free survival，and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer：US Food and Drug Administration trial-level and patient-level analyses［J］.J Clin Oncol，2015，33(9)：1008-1014.
［3］Aupérin A，Le Péchoux C，Rolland E，et al.Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer［J］.J Clin Oncol，2010，28(13)：2181-2190.
［4］Bradley JD，Paulus R，Komaki R，et al.Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer(RTOG 0617)：a randomised，two-by-two factorial phase 3 study［J］.Lancet Oncol，2015，16(2)：187-199.
［5］Fleckenstein J，Kremp K，Kremp S，et al.IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC：A direct comparison of PET-based treatment planning［J］.Strahlenther Onkol，2016，192(2)：75-82.
［6］Ling DC，Hess CB，Chen AM，et al.Comparison of toxicity between intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy for locally advanced non-small-cell lung cancer［J］.Clin Lung Cancer，2016，17(1)：18-23.
［7］Garrido P，Engel-Riedel W，Serke M，et al.Final results from a phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer(NSCLC)［J］.Lung Cancer，2015，88(2)：160-166.
［8］Su S，Li T，Lu B，et al.Three-dimensional radiation therapy to the primary tumor with concurrent chemotherapy in patients with stage IV non-small cell lung cancer：results of a multicenter phase 2 study from PPRA-RTOG，China［J］.Int J Radiat Oncol Biol Phys，2015，93(4)：769-777.
［9］Videtic GM，Hu C，Singh AK，et al.A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer：NRG Oncology RTOG 0915(NCCTG N0927)［J］.Int J Radiat Oncol Biol Phys，2015，93(4)：757-764.
［10］Agolli L，Valeriani M，Bracci S，et al.Hypofractionated image-guided radiation therapy(3Gy/fraction）in patients affected by inoperable advanced-stage non-small cell lung cancer after long-term follow-up［J］.Anticancer Res，2015，35(10)：5693-5700.
［11］Hong JC，Salama JK.Dose escalation for unresectable locally advanced non-small cell lung cancer：end of the line［J］? Transl Lung Cancer Res，2016，5(1)：126-133.
［12］Mollà M，Saez J，Ramos M，et al.Hypofractionated 3d Radiotherapy for inoperable T1-3 N0-1 non-small cell lung cancer［J］.Br J Radiol，2016，17：20150824.
［13］Fennell DA，Summers Y，Cadranel J，et al.Cisplatin in the modern era：The backbone of first-line chemotherapy for non-small cell lung cancer［J］.Cancer Treat Rev，2016，44：42-50.
［14］Hu L，Liang G，Yuliang W，et al.Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis：study protocol for a randomized controlled trial(PLC-GC trial)［J］.Trials，2013，14：45.
［15］Rossi A，Chiodini P，Sun JM，et al.Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer：a systematic review and meta-analysis of individual patient data［J］.Lancet Oncol，2014，15(11)：1254-1262.
［16］Jiang Y，Cui L，Wu XJ，et al.Weekly paclitaxel plus concurrent radiotherapy in the treatment of the elderly patients with esophageal cancer［J］.J Basic and Clin，2012，6(25)：489-492.
［17］Cui L，Jiang Y，Chen J，et al.Clinical research in treating locally advanced non-small cell lung cancer with different doses of paclitaxel concurrent radiochemotherapy［J］.Modern Oncology，2015，23(12)：1682-1686.
［18］He XJ，Jiang Y，Wang L，et al.Comparative analysis of docetaxel，gamcitabine or pemetrexed combined with cisplatin in the treatment of advanced non-small cell lung cancer［J］.Modern Diagnosis and Treatment，2015，25(22)：5148-5150.
［19］Cui L，Chen J，Sun YH，et al.Anticoagulation therapy in cancer patients with pre-thrombotic state［J］.Modern Oncology，2016，24(03)：0486-0471.［崔林，陈珏，孙友红，等.抗凝治疗在恶性肿瘤前血栓状态中的应用［J］.现代肿瘤医学，2016，24(3)：468-471.］
［20］Promteangtrong C，Kunawudhi A，Phadungrerk R，et al.18F-FDG PET/Contrast-enhanced ct for initial staging and strategic treatment of non-small cell lung cancer：a prospective study［J］.J Med Assoc Thai，2015，98(10)：1010-1018.
［21］Schmidt-Hansen M，Baldwin DR，Hasler E，et al.PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer［J］.Cochrane Database Syst Rev，2014，11：CD009519.
［22］Movsas B，Hu C，Sloan J，et al.Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer：a secondary analysis of the radiation therapy oncology group 0617 randomized clinical trial［J］.JAMA Oncol，2016，2(3)：359-367.

Memo

Memo:
-
Last Update: 2016-12-01